Form 4: Bicycle Therapeutics CTO Sells Shares for Tax Obligations

Bicycle Therapeutics CTO Michael Skynner sold shares to cover statutory tax withholding obligations related to restricted stock unit vesting, not as a discretionary sale.

Summary

• Michael Skynner, Chief Technology Officer of Bicycle Therapeutics PLC (BCYC), reported sales of ordinary shares.
• On October 2, 2025, 824 ordinary shares were sold at a weighted average price of $8.4 per share, with prices ranging from $8.31 to $8.45.
• On October 3, 2025, an additional 978 ordinary shares were sold at a weighted average price of $8.41 per share, with prices ranging from $8.40 to $8.50.
• These sales were mandated 'sell to cover' transactions to satisfy minimum statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units.
• The sales do not represent discretionary transactions by the Reporting Person.
• Following these transactions, Michael Skynner beneficially owns 118,277 ordinary shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the share sales were non-discretionary and mandated for tax purposes, not indicative of management's view on the company's prospects.

Positives

• The share sales were non-discretionary, mandated by award agreements to cover statutory tax withholding obligations, indicating no change in management's confidence in the company's future.

Negatives

• The transactions resulted in a reduction of Michael Skynner's direct beneficial ownership of ordinary shares by a total of 1,802 shares.

Risks

• No specific risks beyond the general implications of insider transactions were mentioned in the filing.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction for tax purposes, which is common in the biotechnology industry for executives receiving equity compensation. It does not provide insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The reduction in direct insider ownership is minimal and for a non-discretionary reason, thus unlikely to significantly impact shareholder confidence.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The reported transactions are routine 'sell to cover' sales for tax purposes, which are non-discretionary and do not reflect a change in the insider's view of the company's value or future prospects. Therefore, this filing alone does not provide a basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate.

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider Transaction, Michael Skynner, CTO, Restricted Stock Units, Tax Withholding, Share Sale